WebDoctor Encyclopedia

Adnexal carcinomas

Extramammary Paget disease

Extramammary Paget disease is a rare, slow-growing skin cancer that appears as an itchy red patch in the genital, anal or armpit skin. It is often mistaken for eczema and is usually confined to the skin.

Medically reviewed Last reviewed October 17, 2026

What is extramammary Paget disease?

Extramammary Paget disease (EMPD) is a rare, slow-growing skin cancer. It usually appears as a persistent red, itchy patch in the genital area, around the anus or, less often, in the armpit. These are areas of skin rich in apocrine sweat glands.

The cancer cells (Paget cells) are a type of adenocarcinoma (gland-forming cancer). In most cases they stay within the top layer of the skin, the epidermis. This is called intraepidermal or in situ disease, and it rarely spreads. In a minority of patients the cells grow into the deeper skin (invasive EMPD) and can then spread to lymph nodes and other organs.

EMPD is often mistaken for eczema, a fungal infection or psoriasis, so diagnosis can be delayed for months or years. It is different from Paget disease of the breast (nipple), which is almost always linked to an underlying breast cancer. It is also unrelated to Paget disease of bone.

1. How common is it?

Feature Details
Incidence Very rare. In Europe, invasive EMPD affects about 0.6 people per million each year
Age Mostly over 50; peak around 65-70 years
Sex and ethnicity In white populations, women are affected more often. In East Asian populations, men are affected more often. In US men, rates are about four times higher in Asian and Pacific Islander men and about four times lower in Black men than in white men
Trend In US men, the number of cases has been rising by about 3% a year since the late 1970s
Sites Vulva (about 65% of all cases), perianal skin (about 20%; the most common site in men), scrotum, penis and groin; the armpit is rare

2. Types and causes

2.1 Primary and secondary EMPD

The most important question after diagnosis is whether the disease starts in the skin or is a sign of cancer elsewhere.

Type Origin What it means
Primary EMPD Starts in the skin itself Most cases. It may be in situ, invasive, or linked to an underlying sweat-gland (adnexal) adenocarcinoma
Secondary EMPD Spread of an internal cancer into the skin Most often from the rectum or anus (with perianal EMPD) or from the bladder or urethra (urothelial cancer). Rarely from the cervix, prostate or stomach

This classification, proposed for vulvar Paget disease by Wilkinson and Brown in 2002, guides treatment. Secondary EMPD is treated as part of the underlying cancer.

2.2 Causes

The cause of primary EMPD is not known.

  • The cancer cells may come from stem cells in the skin, from apocrine gland ducts or from so-called Toker cells. The exact cell of origin is still debated.
  • Unlike many other genital skin cancers, EMPD is not caused by HPV.
  • It is not contagious and not caused by poor hygiene.
  • People with invasive EMPD have a higher risk of other cancers, especially colorectal and anal cancer, and cancers in the same body region, according to US SEER data.

3. How does it look?

3.1 On the skin

Feature Typical appearance
Colour Red or pink, sometimes with white areas; occasionally brown (pigmented EMPD)
Surface Scaly, moist, weeping, crusted or eroded, often with scratch marks
Shape and edge Usually a single patch or plaque on one side, slowly enlarging, with irregular edges
Extent The disease often spreads further under normal-looking skin than can be seen, and can be multifocal
Warning signs A lump (nodule), thickening, bleeding or an ulcer inside the patch may mean invasive disease

Typical locations:

  • Women: labia majora and minora, clitoral hood and the skin around the vulva.
  • Men: around the anus, the scrotum, the penis and the groin.
  • Both sexes: the armpit, rarely. EMPD outside apocrine-rich skin, for example on the scalp or face, is called ectopic EMPD and is very rare.

A classic clue is a patch that does not improve after 4-6 weeks of standard treatment for eczema or fungal infection.

3.2 With a dermatoscope

Dermatoscopy (skin-surface microscopy) can show white, cloud-like structureless areas and thick branching white lines with white clods, described as “lava lake” structures. These features support the diagnosis but cannot replace a biopsy.

3.3 Under the microscope

Feature Description
Paget cells Large, round cells with pale or clear cytoplasm and large nuclei, scattered singly or in nests through the epidermis
Mucin The cells often contain mucin, which can be shown with special stains (PAS, Alcian blue)
In situ vs invasive In situ: cells confined to the epidermis. Invasive: cells cross into the dermis. Depth of invasion and invasion of lymph or blood vessels are recorded
Underlying tumour The pathologist looks for a sweat-gland adenocarcinoma beneath the patch

3.4 Special stains

Stains help confirm EMPD and separate primary from secondary disease.

Marker Primary EMPD Secondary from bowel Secondary from bladder or urethra
CK7 Positive Variable Positive
CK20 Usually negative Positive Often positive
GCDFP-15 Often positive Negative Negative
CDX2 Negative Positive Negative
Uroplakin III Negative Negative Positive
GATA3 Usually positive Negative Positive

HER2 protein is overexpressed in about 15% of EMPD overall, and more often in deeply invasive and metastatic disease. In a Japanese study of 104 tumours, HER2 overexpression was linked to deep invasion and lymph node spread. HER2 status matters because it can be targeted by drugs.

4. Symptoms

Many people live with symptoms for a long time before diagnosis. In a study of 100 women with vulvar Paget disease, the median duration of itching before surgery was 2 years.

Symptom Notes
Itching The most common symptom; often intense and long-lasting
Burning, soreness or pain Especially when the skin is raw or eroded
A red, scaly or weeping patch Slowly enlarging; does not clear with steroid or antifungal creams
Bleeding or discharge From eroded or ulcerated skin
Pain when passing urine or during sex With vulvar or penile disease
A lump or thickening May indicate invasive disease
Swollen glands in the groin May indicate spread to lymph nodes

Some people have no symptoms, and the patch is noticed by a partner or found at a check-up.

Symptoms of a possible underlying cancer depend on its site. They include blood in the stool or a change in bowel habit (bowel cancer) and blood in the urine (bladder or urethral cancer).

When to see a doctor: any itchy, red or scaly patch in the genital, anal or armpit area that does not clear within about 4-6 weeks of treatment should be checked and, if needed, biopsied.

5. Diagnosis

5.1 Skin biopsy

A skin biopsy is essential. The 2022 US guideline (Kibbi et al.) recommends taking multiple biopsies, including from any nodular or thickened areas, because invasion may be patchy. Mapping biopsies around the visible edge can help show how far the disease extends before surgery.

5.2 Looking for an associated cancer

Once EMPD is confirmed, doctors check for an internal cancer, guided by age and the site of the skin disease.

Site of EMPD Typical checks
Perianal Colonoscopy to look for rectal or anal cancer
Vulva Gynaecological examination, cervical screening, and checks of the urethra and bladder
Around the urethra, penis or scrotum Cystoscopy and urine tests; prostate examination and PSA in men
All patients Examination of the groin lymph nodes; age-appropriate cancer screening such as breast and bowel screening

5.3 Imaging and blood tests

  • Ultrasound of the groin lymph nodes, with a needle sample if a node looks abnormal.
  • CT, MRI or PET-CT for invasive disease, enlarged nodes or suspected spread.
  • CEA (a blood marker) may be raised in metastatic EMPD and can be used to follow treatment.

5.4 Staging

There is no official international staging system for EMPD. A Japanese group proposed a TNM system in 2016, based on 301 patients with invasive tumours.

Stage (Ohara 2016 proposal) Definition
I Invasive tumour 4 mm thick or less and without invasion of lymph or blood vessels; no node or distant spread
II Tumour thicker than 4 mm or with lymphovascular invasion; no node or distant spread
IIIa Spread to one regional lymph node
IIIb Spread to two or more regional lymph nodes
IV Distant spread

In situ (non-invasive) EMPD is not included in this system and has an excellent outlook.

6. Treatment

Treatment is planned by a team that may include dermatologists, gynaecologists or urologists, plastic surgeons, oncologists and pathologists. The main aim is to remove or destroy all the disease while keeping as much normal function as possible.

6.1 Surgery

Surgery is the standard treatment, especially for invasive EMPD.

Method How it works Benefits and drawbacks
Wide local excision Removal of the patch with a margin of normal-looking skin, often 1 cm or more Widely available. Recurrence is common because the disease extends invisibly: 34% recurred at a median of 3 years in one series of vulvar disease
Mohs micrographic surgery Layer-by-layer removal with complete microscopic margin checking during surgery Lower recurrence: 12.2% overall in a pooled analysis, with an odds ratio of 0.20 compared with wide excision. Needs special expertise; long procedures
Reconstruction Skin grafts or flaps to close large wounds Helps restore function and appearance
More extensive surgery (such as vulvectomy) For extensive or recurrent disease Greater effect on urination, sexual function and body image

Lymph nodes: routine sentinel lymph node biopsy or lymph node removal is not recommended by the 2022 guideline. Lymph node surgery is considered when nodes are enlarged or when the tumour is deeply invasive.

6.2 Non-surgical treatment

Non-surgical options can be used for in situ EMPD, when surgery would be too disfiguring, for recurrences, or for people who cannot have an operation.

Treatment How it works Evidence and side effects
Imiquimod 5% cream Stimulates the immune system against the cancer cells; applied 3 times a week for about 16 weeks In the Dutch Paget Trial, 82.6% of 23 women with in situ vulvar disease responded and 52.2% cleared completely. Redness, soreness, tiredness and headache are common, and most patients needed painkillers. A 2023 review of 233 patients found a response rate of 67% and complete response of 48%
Radiotherapy Radiation directed at the skin and, when needed, the lymph nodes Used for patients unfit for surgery, after surgery with positive margins, or for nodal disease. Causes skin soreness and, later, skin thinning and dryness
Photodynamic therapy A light-sensitising cream activated by light Suitable mainly for small, thin lesions; higher recurrence
Laser ablation (CO2) Destroys the top skin layers Useful for thin disease; no tissue for margin checking
Topical 5-fluorouracil Chemotherapy cream Limited evidence; marked skin irritation

6.3 Treatment of metastatic disease

There is no single standard treatment, so care is often individualised and given within trials.

Treatment Evidence Main side effects
Docetaxel with trastuzumab (for HER2-positive disease) In a Japanese phase II trial of 13 patients, 76.9% responded Low white cell count (in all patients), fatigue, hair loss, swelling
Trastuzumab emtansine (T-DM1) (for HER2-positive disease) In the phase II TEMENOS-2 trial (2026), 13 of 14 patients (92.9%) responded, and median progression-free survival was about 17 months Low platelets, liver test changes; rarely lung inflammation
Other chemotherapy Docetaxel alone and combinations based on fluorouracil and platinum have been used; evidence comes mainly from small series Low blood counts, nausea, tiredness

Secondary EMPD is treated according to the underlying cancer, for example rectal or bladder cancer.

7. Outlook

The outlook for most people with EMPD is good, particularly when the disease is confined to the epidermis. The main problem is local recurrence.

Situation What the evidence shows
In situ EMPD Rarely fatal, but recurs often after surgery (reported in about 15-70% after wide excision)
Invasive EMPD, localised 5-year disease-specific survival 94.9% in US SEER data (1,439 patients)
Invasive EMPD, regional spread 5-year disease-specific survival 84.9%
Invasive EMPD, distant spread 5-year disease-specific survival 52.5%
Overall 5-year overall survival is reported at 75-95% in reviews; 91.2% 5-year relative survival for invasive EMPD in Europe

Factors linked to a worse outcome:

  • Lymph node spread, especially to two or more nodes; this is the strongest predictor.
  • Invasion deeper than about 4 mm, or invasion of lymph or blood vessels.
  • A nodule within the patch.
  • Perianal disease, and age over 75 in men.
  • Secondary EMPD and the stage of any associated internal cancer.

8. Follow-up and living with EMPD

8.1 Follow-up

The 2022 guideline recommends close follow-up for at least the first 5 years, and many specialists continue for longer because recurrences can be late.

Part of follow-up Details
Skin examination The treated area and surrounding skin; any new red or itchy area is biopsied
Lymph nodes Examination of the groin or armpit; ultrasound if needed
Cancer screening Age- and site-appropriate checks, as there is a higher risk of other cancers
Scans and CEA For invasive or metastatic disease

8.2 Everyday life

  • Treatment in the genital area can affect urination, sexual function and body image. Specialist nurses, pelvic floor physiotherapy and psychosexual counselling can help.
  • Gentle, fragrance-free washes and emollients can soothe the skin. Avoid irritants and tight clothing.
  • Do not keep using steroid creams on a patch that is not healing without seeing a doctor.
  • Report any new itching, redness, bleeding or lumps promptly, even years after treatment.

9. Frequently asked questions

Question Answer
Is EMPD a sexually transmitted infection? No. It is a skin cancer, it is not caused by HPV and it cannot be passed to a partner
Is it the same as Paget disease of the breast or bone? No. Breast Paget disease affects the nipple and is linked to breast cancer; Paget disease of bone is not a cancer
Will it spread? Most EMPD stays in the skin. Invasive disease can spread, which is why biopsies of any lumps are important
Why did my patch come back after surgery? The disease often extends invisibly beyond the visible edge. Recurrence is common and can usually be treated again
Can it be treated without surgery? Yes, for many in situ cases. Imiquimod, radiotherapy, photodynamic therapy and laser are options, although surgery may give higher cure rates
Do I need tests for other cancers? Yes. Checks of the bowel, bladder and other organs, depending on where the EMPD is, are part of standard care

Resources

  1. WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  2. Kibbi, N. et al. (2022) ‘Evidence-based clinical practice guidelines for extramammary Paget disease’, JAMA Oncology, 8(4), pp. 618-628.
  3. Kanitakis, J. (2007) ‘Mammary and extramammary Paget’s disease’, Journal of the European Academy of Dermatology and Venereology, 21(5), pp. 581-590.
  4. Morris, C.R. and Hurst, E.A. (2020) ‘Extramammary Paget disease: a review of the literature – Part I: history, epidemiology, pathogenesis, presentation, histopathology, and diagnostic work-up’, Dermatologic Surgery, 46(2), pp. 151-158.
  5. Morris, C.R. and Hurst, E.A. (2020) ‘Extramammary Paget’s disease: a review of the literature Part II: treatment and prognosis’, Dermatologic Surgery, 46(3), pp. 305-311.
  6. Wilkinson, E.J. and Brown, H.M. (2002) ‘Vulvar Paget disease of urothelial origin: a report of three cases and a proposed classification of vulvar Paget disease’, Human Pathology, 33(5), pp. 549-554.
  7. van der Zwan, J.M. et al. (2012) ‘Invasive extramammary Paget’s disease and the risk for secondary tumours in Europe’, European Journal of Surgical Oncology, 38(3), pp. 214-221.
  8. Herrel, L.A. et al. (2015) ‘Extramammary Paget’s disease in males: survival outcomes in 495 patients’, Annals of Surgical Oncology, 22(5), pp. 1625-1630.
  9. Karam, A. and Dorigo, O. (2012) ‘Treatment outcomes in a large cohort of patients with invasive extramammary Paget’s disease’, Gynecologic Oncology, 125(2), pp. 346-351.
  10. Karam, A. and Dorigo, O. (2014) ‘Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease’, British Journal of Dermatology, 170(3), pp. 661-671.
  11. Fanning, J. et al. (1999) ‘Paget’s disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget’s disease, and recurrence after surgical excision’, American Journal of Obstetrics and Gynecology, 180(1 Pt 1), pp. 24-27.
  12. Tanaka, R. et al. (2013) ‘Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease’, British Journal of Dermatology, 168(6), pp. 1259-1266.
  13. Ohara, K. et al. (2016) ‘A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors’, Journal of Dermatological Science, 83(3), pp. 234-239.
  14. Bae, J.M. et al. (2013) ‘Mohs micrographic surgery for extramammary Paget disease: a pooled analysis of individual patient data’, Journal of the American Academy of Dermatology, 68(4), pp. 632-637.
  15. van der Linden, M. et al. (2022) ‘The Paget Trial: topical 5% imiquimod cream for noninvasive vulvar Paget disease’, American Journal of Obstetrics and Gynecology, 227(2), pp. 250.e1-250.e8.
  16. Mayo-Martínez, F. et al. (2023) ‘Topical imiquimod in primary cutaneous extramammary Paget’s disease: a systematic review’, Cancers, 15(23), 5665.
  17. Edey, K.A. et al. (2019) ‘Interventions for the treatment of Paget’s disease of the vulva’, Cochrane Database of Systematic Reviews, 6, CD009245.
  18. Hirai, I. et al. (2024) ‘Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget’s disease (EMPD-HER2DOC)’, The Oncologist, 29(9), pp. e1201-e1208.
  19. Arakawa, S. et al. (2026) ‘Efficacy and safety of trastuzumab emtansine in patients with advanced human epidermal growth factor receptor 2-positive extramammary Paget’s disease: an investigator-initiated, open-label, single-arm, multicentre, prospective, phase II clinical trial (TEMENOS-2)’, ESMO Open, 11(9), 108282.
  20. DermNet (2020) Extramammary Paget disease of skin. Available at: https://dermnetnz.org/topics/extramammary-paget-disease (Accessed: October 2026).

Prepared by the editorial team, October 2026.